



Business Results

Fiscal Year Ended March 31, 2017

Financial Highlights and Mid-Term Management Plan

The Sysmex Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2017. Figures for the previous fiscal year are also disclosed in compliance with IFRS.

Sysmex Corporation

Hisashi Ietsugu,
Chairman and CEO

May 11, 2017

Contents

Chapter 1	Financial Highlights for the Fiscal Year Ended March 31, 2017
Chapter 2	Review of Previous Mid-Term Management Plan (Announced in May 2015)
Chapter 3	Mid-Term Management Plan (Fiscal Years Ending March 31, 2018 to 2020)
Chapter 4	Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2018
Appendix	Mid-Term Management Targets


Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

Chapter 1

Financial Highlights for the Fiscal Year Ended March 31, 2017

Financial Highlights



	Fiscal year ended March 31, 2017	Fiscal year ended March 31, 2016
1USD	¥108.4	¥120.1
1EUR	¥118.8	¥132.6
1CNY	¥16.1	¥18.9

	Fiscal year ended March 31, 2017		Fiscal year ended March 31, 2016		YOY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net sales	249.8	100%	252.6	100%	98.9%
Cost of sales	108.1	43.3%	101.9	40.3%	106.1%
SG&A expenses	75.4	30.2%	74.5	29.5%	101.1%
R&D expenses	15.5	6.2%	15.4	6.1%	100.9%
Other income (expenses)	0.8	0.4%	0.02	0.0%	-
Operating profit	51.7	20.7%	60.7	24.0%	85.1%
Profit attributable to owners of the parent	40.6	16.3%	39.2	15.5%	103.5%

- **Net sales:** The Company recorded growth in all geographic regions on a local currency basis, but sales were down on a yen basis due to the significant impact of yen appreciation.
- **Operating profit:** Profit was down, due to the impact of yen appreciation and a worsening cost of sales ratio.
- **Exchange loss (gains):** Loss of ¥2.21 billion (¥2.74 billion in the previous fiscal year) Exchange rate fluctuations lowered net sales ¥26.41 billion and operating profit ¥11.18 billion. At the exchange rates prevailing one year earlier, net sales would have been up 9.4% and operating profit up 3.5%. Excluding the impact of exchange rate fluctuations and one-off factors, operating profit would have been up 5.7%.
- **Profit attributable to owners of the parent:** Profit was affected by a revised tax treaty with Germany (+¥5.12 billion).


Breakdown of Net Sales and Operating Profit




(Billions of yen)

Net Sales

Note: FX impact excluded from sales by geographic region



Operating Profit




Breakdown of Assets and Liabilities/Equity



(Billions of yen)


Assets

Current assets: Up ¥8.0 billion
 Non-current assets: Up ¥7.8 billion



Liabilities/Equity


Liabilities: Down ¥11.5 billion
 Equity: Up ¥27.4 billion



Consolidated Cash Flows



(Billions of yen)



*Includes translation differences on cash and cash equivalents.

Months indicate the dates of press releases issued by Sysmex.

Management, Business

- Sysmex and Siemens extend long-standing global partnership in hemostasis testing (April)
- Sysmex Asia Pacific establishes branch in Myanmar (May)
- Announcement of plans to reinforce the sales and service structure in Taiwan through the transfer of business from a distributor (commencement of direct sales in May 2017)
- Sysmex acquires additional shares in RIKEN GENESIS and converts company to a subsidiary, reinforcing structure toward the practical realization of genomic medicine (June)
- Sysmex signs agreement with prominent commercial lab in the United States (November)

Products, Technologies

- Sysmex, Astellas and Daiichi Sankyo sign memorandum of understanding on the creation of a method for analyzing circulating tumor cells (December)
- Sysmex enters into research collaboration agreement in relation to cancer and rare diseases with the University of Tokyo, aiming for the clinical application of genomic medicine (February)
- Cancer-related gene panel testing system designated under the Ministry of Health, Labour and Welfare's Sakigake Designation System (March)

Others

- Sysmex selected for inclusion in the Dow Jones Sustainability World Index for the first time (September)
- Sysmex selected as one of the 2017 Global 100's Most Sustainable Companies in the World (January)

Net Sales by Geographic Region




(Billions of yen)

Net Sales by Geographic Region (Sales to External Customers)						
	Fiscal year ended March 31, 2017 Results Ratio		Fiscal year ended March 31, 2016 Results Ratio		YOY (Previous period = 100%) (Yen) (Local currency)	
	Net sales	249.8	100%	252.6	100%	98.9%
Americas	56.5	22.6%	55.9	22.1%	101.1%	112.1%
EMEA	64.9	26.0%	68.4	27.1%	94.8%	105.9%
Region China	60.3	24.1%	65.1	25.8%	92.6%	108.3%
AP	21.1	8.5%	20.0	8.0%	105.5%	(113.4%)
Japan*	46.9	18.8%	43.0	17.0%	109.0%	-

*Includes sales to IDEXX and other external customers

Exchange Rates		
	Fiscal year ended March 31, 2017	Fiscal year ended March 31, 2016
1USD	¥108.4	¥120.1
1EUR	¥118.8	¥132.6
1CNY	¥16.1	¥18.9

● Percentage of Sales in Emerging Markets



Sales by Business



(Billions of yen)



	Fiscal year ended March 31, 2017		Fiscal year ended March 31, 2016 ¹		YOY (Previous = 100%)	Reference: YOY at Previous Year's Rate
	Results	Ratio	Results	Ratio		
Hematology	159.4	63.8%	159.1	63.0%	100.2%	110.7%
Urinalysis	16.1	6.4%	17.5	6.9%	91.9%	102.9%
HU-BU	175.5	70.3%	176.7	69.9%	99.4%	109.9%
Immunochemistry	8.0	3.2%	7.7	3.1%	103.7%	111.9%
Clinical Chemistry	3.3	1.4%	3.5	1.4%	94.2%	102.0%
Hemostasis	40.9	16.4%	44.1	17.5%	92.6%	104.5%
ICH-BU	52.3	20.9%	55.5	22.0%	94.3%	105.4%
LS-BU	4.6	1.8%	3.3	1.4%	136.2%	148.5%
Others ²	17.3	7.0%	17.0	6.7%	102.1%	108.6%
Net sales	249.8	100.0%	252.6	100.0%	98.9%	109.4%

1 Fiscal year ended March 31, 2016: Figures have been adjusted to align with changes in certain categories from the first three months of the fiscal year ended March 2017. Amounts formerly included in "Others" in "HU-BU" have been reclassified to "Others."

2 Others: Clinical laboratory information systems (formerly included in "Others" in HU-BU) sales of third-party products (formerly included in "Other IVD"), FCM products for research and industry, etc.

HU-BU: HU Business Unit (hematology and urinalysis fields)
 ICH-BU: ICH Business Unit (immunochemistry, clinical chemistry and hemostasis fields)
 LS-BU: LS Business Unit (life science field)

Geographic Segment Information: Americas



*Revision in intragroup transaction prices

Copyright by Sysmex Corporation



(Billions of yen)	Fiscal year ended		YOY (Previous period = 100%)	
	March 31, 2017	March 31, 2016	(Yen basis)	(Local currency basis)
Sales	56.5	55.9	101.1%	112.1%
Operating profit*	3.2	1.9	164.6%	182.4%

- Sales rose by double digits on a local currency basis, thanks to expansion of the hematology field in the United States. Due to the impact of yen appreciation, however, sales were up only slightly on a yen basis.
- Operating profit grew, due to the impact of higher sales, a temporary halt in excise taxes (+¥0.40 billion) and a revision in intragroup transaction prices.

Local Currency Basis

- **United States:** Sales increased, due to favorable results in the hematology field stemming from a strategic focus on the West Coast area and the acquisition of a project from a prominent commercial lab.
- **Central and South America:** Although benefiting from the acquisition of a large-scale government tender in Mexico, sales were down due to economic stagnation in Brazil.

Geographic Segment Information: EMEA



*Revision in intragroup transaction prices

Copyright by Sysmex Corporation

EMEA: Europe, the Middle East and Africa

(Billions of yen)	Fiscal year ended March 31, 2017	Fiscal year ended March 31, 2016	YOY (Previous period = 100%)	
			(Yen basis)	(Local currency basis)
Sales	64.9	68.4	94.8%	105.9%
Operating profit*	4.9	4.3	115.7%	129.1%

- On a local currency basis, sales rose due to expanded sales in France, Germany and other advanced countries, as well as to increasing sales in Turkey, Russia and other emerging markets. However, sales were down on a yen basis, owing to the impact of yen appreciation.
- Operating profit rose because of a revision in intragroup transaction prices and efforts to constrain SG&A expenses.

Note: Absent the impact of Partec and Inostics, sales would have been down 3.8%, and operating profit up 11.7% on a yen basis. On a local currency basis, sales would have been up 7.3% and operating profit up 24.7%.



Ignoring the impact of exchange rates on currencies in the EMEA region as well as the factors mentioned above, sales would have been up 8.8%.

Local Currency Basis

- **Five major countries:** Sales grew on increased sales in the urinalysis and hemostasis fields in France, spurred by the start of direct sales, despite some delays on bid projects in the United Kingdom due to the impact of Brexit.
- **Eastern Europe, Russia:** Sales rose, as a growing installed instrument base pushed up reagent sales in the hematology and hemostasis fields in Russia.
- **Middle East, Africa:** Sales increased due to higher sales of reagents, owing to a higher installed instrument base in the hematology field in Iran and Saudi Arabia.

Sysmex Corporation

Geographic Segment Information: China



*Revision in intragroup transaction prices

Copyright by Sysmex Corporation

(Billions of yen)	Fiscal year ended March 31, 2017	Fiscal year ended March 31, 2016	YOY (Previous period = 100%)	
			(Yen basis)	(Local currency basis)
Sales	60.3	65.1	92.6%	108.3%
Operating profit*	3.5	5.8	61.1%	71.5%


- Sales were up on a local currency basis due to higher reagent sales in each field, despite the impact of distributor inventory adjustments on sales of instruments. However, sales were down on a yen basis, due to the impact of yen appreciation.
- The impact of yuan depreciation against the US dollar caused the price of (dollar-denominated) purchases from Japan to rise, prompting a worsening cost of sales ratio and a sharp fall in operating profit.

- **Hematology:** Sales were up slightly thanks to higher reagent sales, despite lackluster sales of instruments.
- **Hemostasis:** Sales grew due to favorable reagent sales, driven by growing demand for thrombosis testing.
- **Urinalysis:** Sales were up slightly due to higher reagent sales despite slower sales of instruments in the lead-up to new product launches.
- **Immunochemistry:** Sales of reagents grew due to an increase in the operating instrument base, but sales of instruments were down.

Geographic Segment Information: AP



Billions of yen



*Revision in intragroup transaction prices

(Billions of yen)	Fiscal year ended March 31, 2017	Fiscal year ended March 31, 2016	YOY (Previous period = 100%) (Yen basis)
Sales	21.1	20.0	105.5%
Operating profit*	1.8	2.3	79.0%

- Sales were up due to increases in the hematology field and favorable performance in the hemostasis and immunochemistry fields, despite the impact of yen appreciation on currencies in the AP region.
- Operating profit fell as a result of a worsening cost of sales ratio, as instruments made up a greater proportion of the sales mix and due to the impact of yen appreciation on currencies in the AP region.

Note: Excluding the impact of exchange rates on currencies in the AP region, sales would have been up 13.4%.


- **Southeast Asia:** Sales rose, due to favorable performance in the hematology field in Vietnam and increased sales of instruments in the hematology and immunochemistry fields in Indonesia stemming from inroads in the introduction of national health insurance.
- **Oceania:** Sales increased substantially, thanks to the acquisition of a large-scale project in Australia in the hematology field.
- **South Korea, Taiwan:** Sales decreased in South Korea, owing to the impact of yen appreciation (but rose on a local currency basis).

Geographic Segment Information: Japan



Billions of yen

Japanese standards IFRS



(Fiscal years ended March 31)

- Intra-area transfers: Exports to Group affiliates, others
- Sales to external customers: IDEXX and others
- Sales to external customers: Japan
- Operating profit

*Revision in intragroup transaction prices

(Billions of yen)	Fiscal year ended March 31, 2017	Fiscal year ended March 31, 2016	YOY (Previous period = 100%)
Sales	140.9	144.0	97.9%
Sales to external customers	46.9	43.0	109.0%
Japan	43.4	39.8	109.1%
IDEXX and others	3.4	3.1	108.5%
Intra-area transfers	94.0	101.0	93.1%
Operating profit*	35.6	43.6	81.7%

- **Reagent sales contributed to higher sales in Japan. Sales were down for the geographic region as a whole due to the impact of yen appreciation on exports to Group affiliates (overseas).**
- **Operating profit fell due to a revision in intragroup transaction prices, one-off factors and the effect of yen appreciation on exports to Group affiliates (overseas).**

- **Japan:** Sales increased due to favorable reagent sales in the hematology, urinalysis, immunochemistry and hemostasis fields, plus the impact of converting RIKEN GENESIS to a subsidiary.
- **IDEXX and others:** Sales were up, owing to higher sales to IDEXX of veterinary instruments.



- Expected dividend up ¥6 compared with the fiscal year ended March 31, 2016
- Proposal represents a dividend increase of ¥2 from the revised figure announced during the year (announcement in November: a year-end dividend of ¥28)

	Interim Dividend	Year-End Dividend	Total	Dividend Ratio
Fiscal Year Ended March 31, 2016	¥24	¥28	¥52	27.5%
Fiscal Year Ended March 31, 2017 (Proposed)	¥28	¥30 <small>Note: To be proposed at the 50th Ordinary General Meeting of Shareholders</small>	¥58	29.7%

Chapter 2

Review of Previous Mid-Term Management Plan (Announced in May 2015)

Review of Previous Mid-Term Management Plan (Business Progress)



Reinforce Growth and Profitability

Results

- Increased market share in hematology (U.S. West Coast, penetration into prominent commercial labs, emerging market developments)
- Strengthened sales promotion in emerging markets and low-end markets by launching the XN-L
- Urinalysis field: Expanded portfolio by entering alliances
- Hemostasis field: Promoted CS-Series launch

Tasks

- Launch new products in the urinalysis field (chemistry, sediment)
- Respond to exchange rate fluctuations



Invest in Growth

Results

- Expanded the immunochemistry field in China and Asia
- Stepped up R&D capabilities in liquid biopsy
- Expanded the gene testing business by converting RIKEN GENESIS to a subsidiary

Tasks

- Introduce clinical FCM* *Abbreviation for flow cytometry
- Profitability in the immunochemistry field, elicit synergies from Inostics and Partec following their conversion to subsidiaries

Review of Previous Mid-Term Management Plan (Business Progress)



Promote Reforms

- Human resource recruitment and cultivation
 - Recruited global human resources
 - Made use of the Global Communication Center to strengthen the cultivation of human resources
- Diversity promotion
 - Fostered a pleasant working environment (such as by creating a workplace that fosters the participation and advancement of women)
 - Promoted employment of people with disabilities (establishment of Sysmex Harmony Co., Ltd., in April 2017)
- Strengthen corporate governance
 - Transitioned to a company with an Audit and Supervisory Committee
 - Increased external members of the Managing Board (from one to four)
 - Started applying the International Financial Reporting Standards (IFRS)



Global Communication Center



Training underway

“Eruboshi” certification as an excellent company based on the Act on Promotion of Women’s Participation and Advancement in the Workplace



Sysmex Corporation

Ranked as a company that contributes to the welfare of employees, their families and the local community



Sysmex America Inc.

Chapter 3

Mid-Term Management Plan (Fiscal Years Ending March 31, 2018 to 2020)

External Environment

■ Macro environment

- World situation uncertain, rise of nationalism
- Aging populations (advanced countries)
- Population increases (emerging markets, developing countries)

■ Technological innovation

- Use of big data
- Promotion of AI and robotics technologies

■ Changes in the healthcare market

- Development of advanced medical care (personalized medicine, regenerative medicine, etc.)
- Measures to curtail healthcare costs (advanced countries, China)
- Establishment of healthcare infrastructure (emerging markets, developing countries)
- Entry by companies from other industries, rise of companies from emerging markets

■ Changing social values

- Growing importance of corporate social responsibility

Internal Environment

■ Enhancement of the global sales support structure


- Transition to a direct sales and service structure in Taiwan
- Establishment of a subsidiary in Ghana
- Establishment of a branch in Myanmar

■ Acquisition of technologies and business platforms

- Conversion of RIKEN GENESIS to a subsidiary
- Expansion of technology platforms
- Promotion of open innovation


■ ESG promotion

- Addressing societal issues through business
- Acquisition of diverse human resources (nationality, gender, etc.)
- Reinforcement of governance (company with an Audit and Supervisory Committee)



Positioning of the Long-Term Management Targets

Undisputed global leader in hematology, hemostasis and urinalysis (including alliances)	A leading global player making a contribution to personalized medicine
A leading company in the Asian <i>in vitro</i> diagnostics (IVD) market	An attractive company providing value and confidence
A unique and competitive player in the immunochemistry field	One Sysmex carrying out high-speed management



Positioning of the current mid-term management plan (fiscal years ending March 31, 2018 to 2020)


- A period for attaining the positioning of the long-term management targets
- Promoting reforms in the portfolio in preparation for the period beyond 2020
- 50th anniversary of establishment as a milestone

Mid-Term Management Plan Overview



Net sales	Operating profit	ROE	Operating cash flow	Free cash flow
¥350.0 billion	¥72.0 billion	>20 %	¥55.0 billion	¥30.0 billion

Assumed exchange rate: 1USD=¥110.0, 1EUR=¥115.0, 1CNY=¥16.0



- **Enhance profitability through market expansion in the hematology field**
 - Achieve an undisputed No. 1 position in the United States (strengthen sales promotion on the West Coast, introduction at prominent commercial labs)
 - Strengthen sales to second-tier and lower hospitals in China
 - Realize high rates of growth in emerging markets
- **Expand the urinalysis testing business by increasing new product sales**
 - Realize an efficient work flow for urinalysis testing through a new concept (Urine chemistry + sediment + imaging instrument + data management)
- **Bolster profitability by increasing our global share in the hemostasis field**
 - Accelerate global development by leveraging our alliance with Siemens
 - Accelerate introduction of fibrin reagents* (China, Japan, etc.) *Used to test for clotting abnormalities and thrombosis
- **Expand business and improve profitability in the immunochemistry field in Japan, China and other parts of Asia**
 - Expand business in the hepatic disease domain
 - Launch unique parameters in China and other parts of Asia (hepatic fibrosis test reagents, such as the M2BPGi™ assay kit)
 - Improve profitability by reducing cost of sales and expand sales

- Establish a foundation for the FCM business

- Launch clinical FCM products
- Step up sales promotion for research and industry use

- Increase the life science business

- Promote the lab assay businesses of RIKEN GENESIS and Inostics
- Enter the clinical PCR market, expand business related to gene testing
- Expand the market for rapid detection of lymph node metastasis based on the OSNA™ method

- Commercialize business in other new fields

- Generate business in ultrahigh-sensitivity HISCL™, cervical cancer screening systems, glucose AUC (postprandial hyperglycemia monitoring system) and other new areas



RF-500 flow cytometer
(for research and industry use)



Clinical PCR



LC-1000
(cervical cancer screening systems)





Glucose AUC
(postprandial hyperglycemia
monitoring system)



Ultrahigh-sensitivity HISCL™


- **Enhance manufacturing speed and quality**
 - Strengthen development and production capacity by establishing a bio-diagnostic reagent base
 - Maintain customer trust through high levels of quality and an enhanced system for stable supply
- **Reinforce IT platforms to optimize operating processes**
 - Optimize supply chain processes
 - Optimize engineering chain processes
- **Strengthen human resource cultivation and human resource management to support Group growth**
 - Step up recruiting and cultivation of human resources who are next-generation leaders and who have advanced specialties
 - Foster a working environment that embraces diverse human resources
(Promote further diversity)

E: Environment
S: Society
G: Governance



As we approach our 50th anniversary of establishment, enhance management quality in the aim of becoming a more sustainable company


By increasing profitability and making proactive investments to augment sustainable corporate value while ensuring appropriate shareholder returns, aim to improve ROE.



Dividend Increases for the 16th Consecutive Fiscal Year (Forecast for the Fiscal Year Ending March 31, 2018)



Sysmex aims to maintain a proper balance between aggressive investment, which is designed to sustain steady high growth, and returns to our shareholders as our earning power increases. In terms of returns to shareholders, we intend to provide a stable dividend on a continuous basis and aim for a consolidated payout ratio of 30% under our basic policy of sharing the successes of our operations in line with business performance.



Chapter 4

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2018

Consolidated Earnings Forecast

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2018

Net sales: **¥275.0 billion**

Operating profit: **¥57.0 billion**

Operating margin: **20.7%**

Profit attributable to owners of the parent: **¥41.0 billion**

Profit attributable to owners of the parent to net sales: **14.9%**

Planned investment

Capital expenditure:
¥18.0 billion

Depreciation and
amortization: **¥14.0 billion**


R&D expenditure:
¥17.5 billion

● Assumed Exchange Rates

	Full year	Actual for fiscal year ended March 31, 2017
1USD	¥110.0	¥108.4
1EUR	¥115.0	¥118.8
1CNY	¥16.0	¥16.1

● Exchange Rate Sensitivity






	Net sales (year)	Operating profit (year)
USD	¥0.57 billion	¥0.57 billion
EUR	¥0.41 billion	¥0.12 billion
CNY	¥4.15 billion	¥0.40 billion



Consolidated Earnings Forecast: Sales and Operating Profit by Region



(Billions of yen, fiscal years to March 31)



Appendix

Mid-Term Management Targets

Mid-Term Management Targets



(Billions of yen)

- Consolidated Statement of Income

		Fiscal year ending March 31, 2018	Fiscal year ending March 31, 2020
Net sales	Japan	46.5	56.8
	Overseas	228.5	293.2
Net sales		275.0	350.0
Operating profit		57.0	72.0
	Operating margin	20.7%	20.6%
Profit attributable to owners of the parent		41.0	52.0

- Sales and Operating Profit by Region

		Fiscal year ending March 31, 2018	Fiscal year ending March 31, 2020	
Japan	Sales	Sales to external customers	50.3	61.7
		Intersegment sales	107.6	138.0
	Sales		157.9	199.7
	Operating profit	Operating profit		39.4
Operating margin		25.0%	23.4%	
Americas	Sales to external customers		64.5	80.9
	Operating profit		3.6	5.7
	Operating margin		5.6%	7.0%
EMEA	Sales to external customers		68.0	86.5
	Operating profit		6.0	7.3
	Operating margin		8.3%	7.9%
China	Sales to external customers		67.2	89.8
	Operating profit		6.5	8.6
	Operating margin		9.7%	9.6%
AP	Sales to external customers		25.0	31.1
	Operating profit		2.5	3.5
	Operating margin		10.0%	11.3%

Mid-Term Management Targets



(Billions of yen)

● Sales by Business

		Fiscal year ending March 31, 2018		Fiscal year ending March 31, 2020	
		Sales	Ratio	Sales	Ratio
	Hematology	172.5	62.7%	201.0	57.4%
	Urinalysis	20.0	7.3%	28.0	8.0%
HU business		192.5	70.0%	229.0	65.4%
	Immunochemistry	11.5	4.2%	24.0	6.9%
	Clinical chemistry	3.0	1.1%	3.0	0.9%
	Hemostasis	42.8	15.6%	53.0	15.1%
ICH business		57.3	20.8%	80.0	22.9%
Core businesses		249.8	90.8%	309.0	88.3%
	FCM business	2.6	0.9%	8.0	2.3%
	LS business	7.4	2.7%	14.0	4.0%
	Others	0.5	0.2%	3.0	0.9%
Next core businesses		10.5	3.8%	25.0	7.1%
Others*		14.7	5.3%	16.0	4.6%
Net sales		275.0	100.0%	350.0	100.0%

* Clinical laboratory information systems, sales of third-party products, others

- Planned investment: Fiscal years ending March 31, 2018 to 2020
(three-year cumulative)

Capital expenditure:	¥60.0 billion (including construction of a base for bio-diagnostic reagents)
Depreciation and amortization:	¥50.0 billion
R&D expenditure:	¥62.0 billion

- Exchanged rates: Fiscal years ending March 31, 2018 to 2020

1USD = ¥110.0


1EUR = ¥115.0

1CNY = ¥16.0

Mid-Term Management Targets: Sales and Operating Profit by Geographic Region



(Billions of yen)



We Believe the Possibilities.

Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

Sysmex Corporation

Contact:

IR & Corporate Communication Dept.
Corporate Communication Div.

Phone: +81-78-265-0500

Email: info@sysmex.co.jp

www.sysmex.co.jp/en